Bortezomib Booms For Stada As Russian Problem Remains

Turnaround Strategy Is In The Works In Russia

 
• By Dean Rudge

With group sales rising by double digits in 2019, Stada says it has the firepower to accelerate investment not only in the firm’s own product development but also broadly into external co-development and product in-licensing, to support sustainability and long-term growth.

Rock_Climber_Greece
Stada's sales climbed by 12% in 2019 following the bortezomib launch • Source: Shutterstock

Stada has welcomed “an exceptionally successful financial year” for 2019, with double-digit sales growth largely driven by the successful launch of a ready-to-use, differentiated formulation of Janssen’s Velcade (bortezomib) in 14 European countries midway through the second quarter.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business